- Home
- AEON vs LEXX Comparison
AEON vs LEXX Comparison
Compare AEON & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEON
- LEXX
- Stock Information
- Founded
- AEON N/A
- LEXX 2004
- Country
- AEON United States
- LEXX Canada
- Employees
- AEON N/A
- LEXX N/A
- Industry
- AEON Biotechnology: Pharmaceutical Preparations
- LEXX Biotechnology: Pharmaceutical Preparations
- Sector
- AEON Health Care
- LEXX Health Care
- Exchange
- AEON Nasdaq
- LEXX Nasdaq
- Market Cap
- AEON 36.4M
- LEXX 43.5M
- IPO Year
- AEON N/A
- LEXX N/A
- Fundamental
- Price
- AEON $0.61
- LEXX $2.01
- Analyst Decision
- AEON Strong Buy
- LEXX Strong Buy
- Analyst Count
- AEON 1
- LEXX 2
- Target Price
- AEON $5.00
- LEXX $11.00
- AVG Volume (30 Days)
- AEON 106.3K
- LEXX 148.5K
- Earning Date
- AEON 11-13-2024
- LEXX 01-10-2025
- Dividend Yield
- AEON N/A
- LEXX N/A
- EPS Growth
- AEON N/A
- LEXX N/A
- EPS
- AEON N/A
- LEXX N/A
- Revenue
- AEON N/A
- LEXX $411,019.00
- Revenue This Year
- AEON N/A
- LEXX $82.02
- Revenue Next Year
- AEON N/A
- LEXX $95.09
- P/E Ratio
- AEON N/A
- LEXX N/A
- Revenue Growth
- AEON N/A
- LEXX 34.05
- 52 Week Low
- AEON $0.60
- LEXX $1.20
- 52 Week High
- AEON $17.17
- LEXX $6.85
- Technical
- Relative Strength Index (RSI)
- AEON 28.55
- LEXX 26.93
- Support Level
- AEON $0.60
- LEXX $2.20
- Resistance Level
- AEON $0.88
- LEXX $2.42
- Average True Range (ATR)
- AEON 0.07
- LEXX 0.19
- MACD
- AEON -0.03
- LEXX -0.00
- Stochastic Oscillator
- AEON 2.62
- LEXX 7.27
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.